SCHEMBL120939

SCHEMBL120939

Cc1ccc(-c2ccc(-c3ccc(C)s3)s2)s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.50
MAPT P10636 4/20 0.50
ALDH1A1 P00352 2/20 0.50
HSD17B10 Q99714 2/20 0.50
GFER P55789 1/20 0.50
RAB9A P51151 3/20 0.42
KDM4E B2RXH2 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TP53 P04637 1/20 0.42
HPGD P15428 1/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM5 P08912 1/20 0.42
CHRM1 P11229 1/20 0.42
CHRM3 P20309 1/20 0.42
DAO P14920 1/20 0.40
CASP3 P42574 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11997754 1.00 NPC1 (0.50) NPC1MAPTALDH1A1HSD17B10GFER
SCHEMBL12170048 1.00 NPC1 (0.50) NPC1MAPTALDH1A1HSD17B10GFER
SCHEMBL12982405 1.00 NPC1 (0.50) NPC1MAPTALDH1A1HSD17B10GFER
SCHEMBL12982161 1.00 NPC1 (0.50) NPC1MAPTALDH1A1HSD17B10GFER
SCHEMBL29764 0.97 NPC1 (0.52) NPC1MAPTALDH1A1HSD17B10GFER
SCHEMBL13376691 0.89 APP (0.50) NPC1MAPTALDH1A1HSD17B10GFER
SCHEMBL12887840 0.87 CYP3A4 (0.46) NPC1MAPTALDH1A1HSD17B10GFER
SCHEMBL12982748 0.84 NPC1 (0.41) NPC1MAPTALDH1A1HSD17B10GFER
SCHEMBL8508163 0.84 MAPT (0.42) NPC1MAPTALDH1A1HSD17B10GFER
SCHEMBL13407308 0.84 NPC1 (0.41) NPC1MAPTALDH1A1HSD17B10GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220416167-A1 OSMIUM-CONTAINING CONJUGATED POLYMER AND METHODS THEREOF XIAMEN UNIVERSITY (CN) 2022-12-29 US disclosed
US-11203688-B2 Composite containing organic/metallic hybrid polymer and ionic liquid, electrochromic device in which same is used, and method for manufacturing said composite and device NATIONAL INSTITUTE FOR MATERIALS SCIENCE (JP) 2021-12-21 US disclosed
US-20210317260-A1 POLYMER, COMPOSITION, ELECTROCHROMIC ELEMENT, DIMMING DEVICE, AND DISPLAY DEVICE NATIONAL INSTITUTE FOR MATERIALS SCIENCE (JP) 2021-10-14 US disclosed
WO-2021143690-A1 OSMIUM-CONTAINING CONJUGATED POLYMER, PREPARATION METHOD THEREFOR AND USE THEREOF 厦门大学 2021-07-22 WO disclosed
US-20210141279-A1 ELECTROCHROMIC DEVICE USING ORGANIC/METAL HYBRID POLYMER AND METHOD FOR PRODUCING SAME NATIONAL INSTITUTE FOR MATERIALS SCIENCE (JP) 2021-05-13 US disclosed
US-20210139643-A1 POLYMER COMPOUND AND ORGANIC PHOTOELECTRIC CONVERSION ELEMENT USING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2021-05-13 US disclosed
EP-2379109-B1 COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE BAUSCH HEALTH COMPANIES INC (CA) 2020-10-07 EP disclosed
EP-3674791-A1 ELECTROCHROMIC ELEMENT AND DISPLAY SYSTEM USING SAME National Institute for Materials Science (JP) 2020-07-01 EP disclosed
US-20200192171-A1 ELECTROCHROMIC ELEMENT AND DISPLAY SYSTEM USING SAME NATIONAL INSTITUTE FOR MATERIALS SCIENCE (JP) 2020-06-18 US disclosed
US-10636975-B2 Organic semiconductor element, compound, organic semiconductor composition, and method of manufacturing organic semiconductor film FUJIFILM CORPORATION (JP) 2020-04-28 US disclosed
WO-2002062386-A2 PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION QLT INC. (CA) 2002-08-15 WO disclosed
WO-2002062384-A2 REDUCED FLUENCE RATE PDT QLT INC. (CA) 2002-08-15 WO disclosed
EP-1229937-A2 USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA QLT Inc. (CA) 2002-08-14 EP disclosed
US-20020061330-A1 Supports for photosensitizer formulations BRITISH COLUMBIA, THE UNIVERSITY OF (CA) 2002-05-23 US disclosed
US-6355365-B1 FOR USE IN ORGANIC ELECTRO LUMINESCENCE (EL) DEVICE; EFFICIENCY JAPAN CHEMICAL INNOVATION INSTITUTE (JP) 2002-03-12 US disclosed
US-20020022032-A1 Immuno-adjuvant PDT treatment of metastatic tumors QLT INC. (CA) 2002-02-21 US disclosed
WO-2001085212-A2 DRUG DELIVERY SYSTEMS FOR PHOTODYNAMIC THERAPY THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2001-11-15 WO disclosed
WO-2001035996-A2 USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA QLT INC. (CA) 2001-05-25 WO disclosed
WO-2001035997-A2 USE OF LOW-DOSE PDT TO INHIBIT RESTENOSIS QLT INC. (CA) 2001-05-25 WO disclosed
US-5045563-A Terthienyl Compound HER MAJESTY THE QUEEN IN RIGHT OF CANADA, AS REPRESENTED BY MINISTER OF NATIONAL DEFENCE OF HER MAJESTY'S CANADIAN GOVERNMENT (CA) 1991-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061330-A1 Supports for photosensitizer formulations PPOX, PPIF, SDHA NPC1 1133/4885MAPT 1710/4885ALDH1A1 371/4885
US-20020022032-A1 Immuno-adjuvant PDT treatment of metastatic tumors CD74, ANXA11, ANXA1 NPC1 2358/4885MAPT 1243/4885ALDH1A1 794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.